康泰医学
(300869)
| 流通市值：35.32亿 | | | 总市值：56.01亿 |
| 流通股本：2.53亿 | | | 总股本：4.02亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 111,844,411.72 | 479,805,174.09 | 333,885,288.03 | 211,789,804.52 |
| 营业收入 | 111,844,411.72 | 479,805,174.09 | 333,885,288.03 | 211,789,804.52 |
| 二、营业总成本 | 93,516,783.56 | 467,672,298.13 | 336,662,644.47 | 212,974,691.76 |
| 营业成本 | 46,809,494 | 243,022,612.99 | 167,266,311.47 | 106,962,931.79 |
| 税金及附加 | 3,472,842.69 | 8,463,226.61 | 6,524,487.08 | 4,532,617.97 |
| 销售费用 | 15,862,954.35 | 88,527,030.1 | 56,438,909.91 | 36,429,656.3 |
| 管理费用 | 8,074,873.75 | 40,822,155.41 | 26,684,621.96 | 17,826,736.72 |
| 研发费用 | 22,572,126.74 | 105,156,379.17 | 83,429,418.51 | 56,055,044.05 |
| 财务费用 | -3,275,507.97 | -18,319,106.15 | -3,681,104.46 | -8,832,295.07 |
| 其中:利息费用 | - | 35,299,989.3 | - | - |
| 其中:利息收入 | - | 48,539,438.67 | - | - |
| 加:公允价值变动收益 | 2,307,189.11 | 1,588,083.19 | 916,579.69 | 1,548,798.82 |
| 加:投资收益 | 664,115.06 | 22,518,834.81 | 15,360,687.14 | 11,098,894.68 |
| 资产处置收益 | -16,317.68 | 166,241.78 | 166,241.78 | 7,936.7 |
| 资产减值损失(新) | -6,870,205.28 | -109,445,716.65 | -8,762,780.34 | -6,129,554.46 |
| 信用减值损失(新) | -4,771.71 | -1,820,714.08 | -1,186,588.14 | -1,418,946.35 |
| 其他收益 | 2,817,310.37 | 7,310,075.54 | 6,755,701.03 | 3,984,036.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 17,224,948.03 | -67,550,319.45 | 10,472,484.72 | 7,906,278.51 |
| 加:营业外收入 | 189,886.3 | 1,627,737.34 | 1,376,087.09 | 1,181,427.54 |
| 减:营业外支出 | 268,394.62 | 7,964,744.43 | 690,120.83 | 583,373.73 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 17,146,439.71 | -73,887,326.54 | 11,158,450.98 | 8,504,332.32 |
| 减:所得税费用 | 710,671.93 | 4,015,238.14 | 1,255,523.12 | 337,211.53 |
| 六、净利润 | 16,435,767.78 | -77,902,564.68 | 9,902,927.86 | 8,167,120.79 |
| 持续经营净利润 | 16,435,767.78 | -77,902,564.68 | 9,902,927.86 | 8,167,120.79 |
| 归属于母公司股东的净利润 | 16,435,767.78 | -77,902,564.68 | 9,902,927.86 | 8,167,120.79 |
| (一)基本每股收益 | 0.04 | -0.19 | 0.02 | 0.02 |
| (二)稀释每股收益 | - | -0.17 | - | - |
| 八、其他综合收益 | 138,597.25 | 396,628.48 | -713,854.79 | 78,993.98 |
| 归属于母公司股东的其他综合收益 | 138,597.25 | 396,628.48 | -713,854.79 | 78,993.98 |
| 九、综合收益总额 | 16,574,365.03 | -77,505,936.2 | 9,189,073.07 | 8,246,114.77 |
| 归属于母公司股东的综合收益总额 | 16,574,365.03 | -77,505,936.2 | 9,189,073.07 | 8,246,114.77 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-28 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |